Zobair Younossi, MD, MPH

Zobair Younossi, MD, explains how lifestyle, drugs, and EXCEL data show steatosis and fatigue improvements in MASLD.

EPL reduced hepatic steatosis vs placebo in EXCEL MASLD trial, meeting primary endpoint at 6 months by CAP FibroScan assessment.

Younossi emphasizes the need for NIT-based risk stratification for MASLD, citing his research supporting their widespread adoption across clinical settings.

Younossi explains the growing interest in NITs for MASLD and reviews his research on their performance in age, diabetes, and obesity subgroups.

Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.

Younossi explains the importance of patient-reported outcomes and assessing HRQoL, breaking down findings from an analysis of the MAESTRO-NAFLD trial of resmetirom.